Early versus delayed androgen deprivation for prostate cancer: New fuel for an old debate

Journal of Clinical Oncology

Volumn 23, Issue 32, 2005, Pages 8225-8231

  Ryan, Charles J ^a   Small, Eric J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; FINASTERIDE; FLUTAMIDE; GONADORELIN DERIVATIVE; GOSERELIN; ANTINEOPLASTIC AGENT; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ANDROGEN DEPRIVATION; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; HUMAN; INTERMETHOD COMPARISON; MEDICAL LITERATURE; MEDICAL SOCIETY; METASTASIS; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; REVIEW; BONE TUMOR; DRUG COMBINATION; DRUG EFFECT; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; TIME;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 33644684061     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.5311     Document Type: Review

References (38)

1. Huggins C, Hodges CV: Studies on prostatic cancer, effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293-297, 1941
2. Group: TMRCPCWPI: Immediate versus deferred treatment for advanced prostatic cancer-Initial results of the Medical Research Council Trial. Br J Urol 79:235-246, 1997
3. Byar DP, Corle DK: Hormone therapy for prostate cancer: Results of the Veterans Administration Cooperative Urological Research Group Studies. NCI Monogr 7:165-170, 1988
4. Scher HI, Heller G: Clinical states in prostate cancer: Towards a dynamic model of disease progression. Urology 55:323-327, 2000
5. Kattan MW, Eastham JA, Stapleton AMF, et al: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90:766-771, 1998
6. Roach MD III, Lu J, Pilepich MV, et al: Predicting long-term survival, and the need for hormonal therapy: A meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys 47:617-627, 2000
7. D'Amico AV, Whittington R, Malkowicz SB, et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy of interstitial radiation therapy for clinically localized prostate cancer. J Am Med Assoc 280:969-974, 1998
8. Partin AW, Subong ENP, Walsh PC, et al: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update. JAMA 277:1445-1451, 1997
9. Small EJ, Halabi S, Dawson NA, et al: Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A phase III trial (CALGB 9583). J Clin Oncol 22:1025-1033, 2004
10. Kassouf W, Tanguay S, Aprikian A: Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. J Urol 169:1742-1744, 2003
11. Thompson I, Goodman PM, Tangen CM, et al: The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215-224, 2003
12. Taplin M, Rajeshkumar B, Halabi S, et al: Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B study 9663. J Clin Oncol 21:2673-2678, 2003
13. Taplin ME, Bubley GJ, Ko YJ, et al: Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59:2511-2515, 1999
14. Smith MR, Finkelstein JS, McGovern FJ, et al: Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 87:599-603, 2002
15. Crawford ED, Blumenstein BA, Goodman PJ, et al: Leuprolide with and without flutamide in advanced prostate cancer. Cancer 66:1039-1044, 1990
16. Smith MR: Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology 63:742-745, 2004
17. Salminen EK, Portin RI, Koskinen A, et al: Associations between serum testosterone fall and cognitive function in prostate cancer patients. Clin Cancer Res 10:7575-7582, 2004
18. Bolla M, Collette L, Blank L, et al: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 360:103-106, 2002
19. Pilepich MV, Winter K, Lawton C, et al: Phase III trial of androgen suppression adjuvant to definitive radiotherapy. Long term results of RTOG study 85-31. Proc Am Soc Clin Oncol 22:381, 2003 (abstr 1530)
20. Messing EM, Sarosdy M, Wilding G, et al: Immediate hormonal therapy compared with observation after radical prostatectom and pelvic lymphadenectomy and in men with node positive prostate cancer: Results at 10 years of ECOG 3886. Proc Amer Urol Assoc, 2003 (abstr 1480)
21. See W, Wirth MP, McLeod DG, et al Casodex Early Prostate Cancer Trialist Group.: Bicalutamide ("Casodex") 150 mg as immediate therapy either alone or as adjuvant to standard care in patients with localized or locally advanced prostate cancer: First anlaysis of the early prostate cancer program. J Urol 168:429-435, 2002
22. D'Amico AV, Manola J, Loffredo M, et al: 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 292:821-827, 2004
23. Moul JW, Wu H, Sun L, et al: Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 171:1141-1147, 2004
24. Wallace KL, Elkin EP, Latini DM, et al: Timing of LHRHR treatment after PSA failure in prostate cancer patients: A survival analysis from the CAPSURE database. Proc Am Urol Assoc, 2004 (abstr 434)
25. Pilepich MV, Caplan R, Byhardt RW, et al: Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 15:1013-1021, 1997
26. Lawton CA, Winter K, Murray K, et al: Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 49:937-946, 2001
27. Lawton CA, Winter K, Grignon D, et al: Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: Updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. J Clin Oncol 23:800-807, 2005
28. Messing E, Manola J, Wilding G, et al: Immediate hormonal therapy vs. observation for node positive prostate cancer following radical prostatectomy: A randomized phase III Eastern Cooperative Oncology Group/Inter Group Trial. J Urol 161:673 1999
29. Soloway MS, Pareek K, Sharifi R, et al: Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 167:112-116, 2002
30. Cher ML, Shinohara K, Breslin S, et al: High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostate cancer. Br J Urol 75:771-777, 1995
31. Gleave ME, Goldenberg SL, Chin JL, et al: Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: Biochemical and pathological effects. J Urol 166:500-6; discussion 506-7, 2001
32. (UK) CoSoM: CASODEX 150 mg (bicalutamide): No longer indicated for treatment of localized prostate cancer, http://medicines.mhra.gov .uk/aboutagency/regframework/csm/csmhome.htm, 2003
33. Bianco FJ, Dotan ZA, Kattan MW, et al: Duration of response to androgen deprivation therapy and survival after subsequent biochemical relapse in men initially treated with radical prostatectomy. J Clin Oncol, 2004 (suppl 1; abstr 4552)
34. Petrylak DP, Tangen CM, Hussain MA, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520, 2004
35. Tannock IF, De Wit R, Berry W, et al: Docetaxel plus prednisone for advanced refractory prostate cancer N Engl J Med 351:1502-1512, 2004
36. D'Amico AV, Moul JW, Carroll PR, et al: Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95:1376-1383, 2003
37. Pound CR, Partin AW, Eisenberger MA, et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591-1597, 1999
38. Eisenberger MA, Partin AW, Pound CR, et al: Natural history of progression of patients with biochemical (PSA) relapse following radical prostatectomy: Update. Proc Am Soc Clin Oncol 22:380, 2003 (abstr 1527)